XBiotech Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$45.1MTTM through 30 Jun 2026
Free Cash Flow -$40.8MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-32.5%ROE
-30.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio16.01x
Net Debt-$125.6Mnet cash position
Cash & Equivalents$109.5M
Quality Metrics
Altman Z-Score5.90
Piotroski F-Score1 / 9
Earnings-Beat Rate0.0%
Multi-Year Trend
RevenueFY2023: $0
Diluted EPSFY2025: $-1.49
Dividend
No dividend
Capital Allocation
R&D Spend$40.9M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.